Dupixent® (dupilumab) demonstrated superiority over xolair® (omalizumab) in chronic rhinosinusitis with nasal polyps (crswnp) in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory trial

New late-breaking data at eaaci showed dupixent outperformed xolair across all primary and secondary efficacy endpoints of crswnp and in all asthma-related endpoints

REGN Ratings Summary

REGN Quant Ranking